Phase 2Recruiting
Effects of Different Fish Oil Types on Type 2 Diabetes Risk Factors in High-Risk Adults (END-T2D)
Role of EPA and DHA as Tailored Therapy for People Living With Obesity and High-risk for Type 2 Diabetes (END-T2D): a Randomized Controlled Trial
- Sponsor
- May Faraj, PDt, PhD (Academic or other)
- Enrolment
- 84 planned
- Conditions
- Type 2 Diabetes; Prediabetes (Insulin Resistance, Impaired Glucose Tolerance); Prediabetes / Type 2 Diabetes; Obesity & Overweight; Obesity and Diabetes Mellitus, Type 2
- Interventions
- Fish Oil; Fish Oil; Corn oil control
- Ages
- adults, older adults
- Registry
- NCT07575438
Full record on ClinicalTrials.gov
From the registry
The purpose of this clinical trial is to find out whether one type of fish oil works better than another at improving metabolic health in people who are at high risk of developing type 2 diabetes. Some metabolic problems-such as difficulty controlling blood sugar, unhealthy particles that transport cholesterol in the blood, and poor fat tissue function-can increase the risk of type 2 diabetes. This study aims to determine whether different types of fish oil can: 1. Improve how well the body produces insulin and responds to it, 2. Improve the quality of the particles that carry "bad" cholesterol in the blood, and 3) Improve the health and function of participants' fat tissue. To answer these questions, researchers will compare the effects of two types of fish oil: EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid). These will be compared with corn oil, which is used as a placebo and does not contain EPA or DHA. When included in this study, participants will: A) Take softgel capsules containing EPA, DHA, or placebo (corn oil) every day for 12 weeks, B) Keep a daily log to…
Primary outcomes
- Change from baseline to 12 weeks in the disposition index
History
Primary completion expected
Last registry update
Started
Registered